| Range: | 0.001-0.018 | Vol Avg: | 44032 | Last Div: | 0 | Changes: | -0.01 |
| Beta: | 2.29 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Thu Aug 24 2023 | Empoloyees: | |||
| CUSIP: | CIK: | ISIN: | CA53946V2066 | Country: | CA | ||
| CEO: | Dr. Frederick Dominick Sancilio M.S., Ph.D. | Website: | https://www.lobesciences.com | ||||
LOBEF 0.02 Stock Price Lobe Sciences Ltd.
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow